Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Vitrolife AB's shares outstanding for the quarter that ended in Mar. 2026 was 135 Mil.
Vitrolife AB's quarterly shares outstanding
stayed the same
from Dec. 2025 (135 Mil) to Mar. 2026 (135 Mil).
Vitrolife AB's annual shares outstanding
stayed the same
from Dec. 2024 (135 Mil) to Dec. 2025 (135 Mil).
Vitrolife AB (OSTO:VITR) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Vitrolife AB Shares Outstanding (EOP) Related Terms
Vitrolife AB Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:VITR vs ABT, SYK, MDT: Shares Outstanding (EOP) Comparison
For the Medical Devices subindustry, Vitrolife AB's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB Shares Outstanding (EOP) vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 135 Mil mean?
Vitrolife AB (OSTO:VITR) has a Shares Outstanding (EOP) of 135 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Vitrolife AB and its competitors.
Is Vitrolife AB's Shares Outstanding (EOP) too high?
Vitrolife AB's current Shares Outstanding (EOP) is 135 Mil. Overall, Vitrolife AB has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Shares Outstanding (EOP) compare to ABT and SYK?
Vitrolife AB's Shares Outstanding (EOP) of 135 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Devices & Instruments company?
A good Shares Outstanding (EOP) depends on the Medical Devices & Instruments industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Vitrolife AB and its competitors. Vitrolife AB's current Shares Outstanding (EOP) is 135 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (OSTO:VITR) is currently considered Possible Value Trap. The stock's GF Value™ is kr162.30, compared to a current price of kr89.50 — trading 44.9% below its estimated fair value. The current Shares Outstanding (EOP) is 135 Mil. Vitrolife AB's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Vitrolife AB (OSTO:VITR), the current Shares Outstanding (EOP) is 135 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (OSTO:VITR) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr89.50 is trading 44.9% below its estimated GF Value™ of kr162.30.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for OSTO:VITR:
Shares Outstanding (EOP): 135 Mil
GF Value™: kr162.30 vs. price of kr89.50 (44.9% below fair value)
No single metric tells the full story. See the OSTO:VITR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
79GF Score
Get the complete analysis for OSTO:VITR
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VITR has been successfully added to your 
